A possible explanation for the higher costs in controls and SCD suggests that APOE e4-positive individuals may exhibit greater resilience to remain in a lower stage of the disease due to protective factors, delaying progression and thereby reducing costs. Here, APOE is linked to Schnyder corneal dystrophy.